Supernus Pharmaceuticals demonstrated strong growth in core products Qelbree and GOCOVRI, introduced a promising new product ONAPGO, and maintained a solid cash position. However, these positives were offset by significant declines in legacy products and an increased operating loss, resulting in an overall net loss for the quarter.

Company Guidance -

Q2 2025

During Supernus Pharmaceuticals' first quarter 2025 financial results conference call, guidance was reiterated for the full year, projecting total revenues to range from $600 million to $630 million, driven primarily by net product sales and royalty revenue. The company maintained its estimates for combined R&D and SG&A expenses to be between $435 million and $460 million. Non-GAAP operating earnings are expected to range from $105 million to $130 million, while GAAP operating earnings are projected to vary from a $15 million loss to a $10 million profit. The call highlighted a 26% increase in total revenues, excluding legacy products Trokendi XR and Oxtellar XR, due to the strong performance of Qelbree and GOCOVRI. Qelbree saw a 22% rise in prescriptions and a 44% jump in net sales, while GOCOVRI experienced a 12% increase in prescriptions and 16% growth in net sales. For the remainder of 2025, combined net sales of Trokendi XR and Oxtellar XR are expected to decrease, with guidance maintained at $65 million to $75 million. Supernus also launched ONAPGO, a subcutaneous apomorphine infusion device for Parkinson's disease, which received encouraging initial feedback from physicians.

Double-Digit Revenue Growth

Total revenues, excluding Trokendi XR and Oxtellar XR, increased by 26% in the first quarter compared to the same quarter last year.

Qelbree Performance

Qelbree grew by 22% in prescriptions and by 44% in net sales. Monthly prescriptions in March reached an all-time high of 75,277, up 25% compared to the same period last year.

GOCOVRI Growth

Prescriptions for GOCOVRI increased by 12% and net sales increased by 16% compared to the same quarter last year, with Medicare prescriptions costing patients less than $25 for 84% of prescriptions.

Launch of ONAPGO

Launched ONAPGO, a new growth product for Parkinson's disease, with initial positive response from physicians and more than 75% of sales territories generating patient enrollment forms.

Strong Cash Position

The company had approximately $463.6 million in cash, cash equivalents, and marketable securities, maintaining a strong balance sheet.

Supernus Pharmaceuticals (SUPN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SUPN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 05, 2025	2025 (Q2)	0.47 / -	0.771	―	―	―
May 06, 2025	2025 (Q1)	0.37 / 0.44	0.46	-4.78% (-0.02)	―
Feb 25, 2025	2024 (Q4)	0.52 / 0.75	0.883	-15.52% (-0.14)	―
Nov 04, 2024	2024 (Q3)	0.44 / 1.17	-0.29	502.76% (+1.46)	―
Aug 06, 2024	2024 (Q2)	0.39 / 0.77	-0.02	3955.00% (+0.79)	―
May 08, 2024	2024 (Q1)	0.38 / 0.46	0.29	58.62% (+0.17)	―
Feb 27, 2024	2023 (Q4)	0.55 / 0.88	0.43	105.35% (+0.45)	―
Nov 08, 2023	2023 (Q3)	<0.01 / -0.29	0.03	-1066.67% (-0.32)	―
Aug 08, 2023	2023 (Q2)	0.21 / -0.02	0.546	-103.66% (-0.57)	―
May 09, 2023	2023 (Q1)	0.31 / 0.29	0.43	-32.56% (-0.14)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SUPN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 06, 2025	$32.43	$30.94	-4.59%
Feb 25, 2025	$32.81	$31.91	-2.74%
Nov 04, 2024	$34.70	$34.74	+0.12%
Aug 06, 2024	$27.88	$31.92	+14.49%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Supernus Pharmaceuticals (SUPN) report earnings?

Supernus Pharmaceuticals (SUPN) is schdueled to report earning on Aug 05, 2025, After Close (Confirmed).

What is Supernus Pharmaceuticals (SUPN) earnings time?

Supernus Pharmaceuticals (SUPN) earnings time is at Aug 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SUPN EPS forecast?

SUPN EPS forecast for the fiscal quarter 2025 (Q2) is 0.47.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing